Abstract: ²¹¹At, produced by cyclontron, is a promising radioisotope for tumor targeted radiotherapy due to its favorable radiobiological characteristics and cytotoxicity. The progress of radiopharmaceuticals labeled with ²¹¹At were reviewed with 50 references in recent years, including the preparation of ²¹¹At, the experimental and clinical research of labeled compounds, labeling methods, etc. Additionally, its situation, problems and prospect were discussed.